Document:

Manufacturing and Supply Agreement

 EXHIBIT 10.2 
 Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated by ***. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission. 
 MANUFACTURING AND SUPPLY AGREEMENT 
 THIS AGREEMENT (“Agreement”) is made and entered into this 23rd day of May 2006, (“Effective Date”) by and between Merck Eprova AG, a
Swiss corporation, having a place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland (“EPRO”) and Spectrum Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 157 Technology Drive, Irvine,
California, 92618, United States (“SPECTRUM”). EPRO and SPECTRUM may hereinafter each be referred to as a “Party” or collectively as the “Parties”. Capitalized terms used in this Agreement shall have the meaning set
forth herein or in the License Agreement (as defined below). 
 WITNESSETH: 
 WHEREAS, SPECTRUM is licensing certain technology from EPRO (the “Technology”) pursuant to a License Agreement dated May 23, 2006 executed
by the Parties herewith (the “License Agreement”); 
 WHEREAS, EPRO is engaged in the business of manufacturing drug substances and
it has the expertise and appropriate government approvals necessary to manufacture the drug substance incorporating the Technology; 
 WHEREAS, EPRO and SPECTRUM have agreed to the following terms and conditions, and desire to enter into this Manufacturing and Supply Agreement (the “Agreement”); and 
 WHEREAS, it is the desire and intention of SPECTRUM that EPRO use the Technology to manufacture or have manufactured the drug substance Calcium
Levofolinate (hereinafter “Product”), upon the terms and conditions hereinafter set forth. 
 NOW, THEREFORE, the Parties, in
consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and with the Parties intending to be legally bound do hereby
agree as follows: 
 Article 1 Product Manufacture 
 (a) During the term of this Agreement, SPECTRUM shall from time to time, place orders with EPRO . EPRO shall process and deliver the Product pursuant to such orders, in compliance with the Specifications as defined in
Exhibit A attached hereto. 
 EPRO shall have the right to require SPECTRUM to pay ***. 
 (b) EPRO shall manufacture and have ready for shipment the ordered quantities of the 

  

 - 1 - 

 
Product within *** from receipt of a written purchase order from SPECTRUM hereunder. SPECTRUM shall furnish EPRO with its *** forecast on the Effective Date
and every *** with its rolling forecast for the following *** period for the Product, however, any such estimates shall not be binding or otherwise limit or obligate SPECTRUM in any way except for the first *** which shall be binding and shall be
referred to as the “Minimum Quantities.” 
 (c) From time to time during the term of this Agreement, the Parties by mutual consent,
may add to or modify the Specifications attached hereto as Exhibit A by reasonable advance written notice. EPRO will update its drug master file (DMF) every time the drug substance specifications are changed. 
 (d) EPRO shall not actively manufacture the Product for any third party for the Field of Use in the Territory and shall cooperate in good faith with
Spectrum to insure that Product sold to any third party shall not be re-sold or used by that Party in the Field of Use in the Territory. 
 (e) SPECTRUM shall purchase its Product requirements exclusively from EPRO during the term of this Agreement. 
 (f) EPRO shall not
manufacture or sell any product using the Technology or license its knowledge of the Technology to enable other manufacturers to make available the Product in the Field of Use in the Territory. 
 (g) EPRO shall manufacture the Product at its facility located at Schaffhausen, Switzerland (“EPRO’s Facility”), which facility will have
to be inspected and approved by SPECTRUM prior to shipment of any commercial Product, and meets with all FDA requirements. EPRO will use commercially reasonable efforts to file a Drug Master File (“DMF”) for the manufacture of the Product
before *** and will be responsible for all associated costs. EPRO hereby represents and warrants that EPRO’s Facility, including the real estate on which it is situated and all equipment located therein is now, and shall be for the term of this
Agreement, owned and operated solely by EPRO or an Affiliate thereof. EPRO, at its expense, shall furnish upon written request from SPECTRUM, the complete filing of the DMF directly to the United States Food and Drug Administration (“FDA”)
under confidentiality obligations prior to SPECTRUM’s submission to the FDA of its deficiency response associated with the New Drug Application (“NDA”) for the Product, and the “open part” of the DMF to SPECTRUM. EPRO shall
also furnish, at its expense, all available equivalent documentation to the regulatory authorities in Canada and Mexico to support future regulatory filings in those territories where SPECTRUM has marketing rights, in addition to any other
documents, as may be reasonably requested by SPECTRUM and are available at EPRO, related to the Drug Master File. 
 (h) After NDA-approval
of a Licensed Product, EPRO shall be required to maintain an inventory of at least *** of the Product, and will promptly manufacture said Product upon the receipt of a purchase order. 
 Article 2 Prices 
 (a) SPECTRUM shall pay to EPRO in full and complete consideration for the
manufacture, control and delivery of the Product hereunder, the price as specified in Article 2(b) and (c) hereof (the “Price”). EPRO shall supply all materials necessary for the manufacture and 

  

 - 2 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 
packaging of the Product. 
 (b) During the term
of this Agreement, the Price of the Product shall be *** per *** calculated as *** from the Effective Date until ***. 
 (c) SPECTRUM shall
pay to EPRO the actual Price of the Product delivered to SPECTRUM hereunder. On ***, and thereafter each ***, the Price of the Product may be renegotiated by the mutual agreement of both Parties. SPECTRUM shall be able to obtain competitive prices
and if SPECTRUM is able to obtain a lower price from another manufacturer in a bonafide third party offer for Product in commercial quantities and similar quality (i.e. Product should be acceptable by the health authorities and the alternative
supplier shall give proof of its commitment to file a respective DMF for the Territory), then SPECTRUM shall be able to terminate this Agreement and use the other manufacturer provided that EPRO shall have the opportunity to meet such competitive
offer price in which case SPECTRUM shall continue to purchase its total demand of Product from EPRO until the following ***. 
 Article 3 Raw Materials
and Packaging 
 (a) All ingredients and raw materials used by EPRO for the manufacture of the Product shall conform to the set
Specifications and must meet the requirements of the FDA for current Good Manufacturing Practices (“cGMP”) compliance. 
 (b) EPRO
will package the Product according to EPRO’s most recent packaging guidelines, which are set forth in Exhibit B hereto, and label the Product in accordance with FDA’s and applicable labeling regulations, so that the Product is
ready-to-ship to a third party toll manufacturer for finished good production. 
 (c) EPRO agrees to inform SPECTRUM within fifteen (15) days
of the result of any regulatory development or major changes in specifications of the raw materials and/or of the Product that may materially affect the Product. EPRO shall notify SPECTRUM of and require written approval from SPECTRUM for changes as
agreed in the Quality Agreement. 
 (d) The capitalized terms in this Article 3 shall have the meaning set forth below: 
  

	 	a.	BATCH shall mean a specific quantity of Product comprising a number of units mutually agreed upon between SPECTRUM and EPRO, and that (a) is intended to have uniform character
and quality within specified limits, and (b) is produced according to a single manufacturing order during the same cycle of Production. 

  

	 	b.	Master Batch Record (MBR) shall mean the formal set of instructions for the Production of Product. The MBR will be developed and maintained in EPRO’s standard format.

  

	 	c.	Production or Product shall mean the manufacturing operation including compounding, filling, packaging, inspection, labeling, and testing of the Product by EPRO.

  

 - 3 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 Article 4 Delivery, Payment and Title to Product 
 (a) All Product shipments shall be delivered to SPECTRUM or a designated toll manufacturer, *** pursuant to SPECTRUM’s written directions. EPRO shall
furnish to SPECTRUM sufficient information to verify shipment of the Product. 
 (b) EPRO shall invoice SPECTRUM for the Product on the date
such Product shipment is shipped from EPRO’s Facility on instructions from SPECTRUM. Terms of payment shall be net *** from the date of such invoice. Late payments must bear *** (***) percent interests per annum. 
 SPECTRUM shall bear the risk of loss or damage to any Product after the same shall have been delivered to the possession of either SPECTRUM, the toll manufacturer or to
SPECTRUM’s carrier pursuant to SPECTRUM’s instructions, except for loss or damage caused by the manufacturing, processing, packaging, or quality of the Product, in which case such loss or damage shall be borne solely by EPRO. EPRO shall
bear the risk of loss or damage to any Product ordered hereunder prior to the delivery of such Product to SPECTRUM, the toll manufacturer or to the carrier designated by SPECTRUM for transportation thereof. 
 Article 5 Inspection, Manufacturing Compliance, Acceptance of Product 
 (a) SPECTRUM may once per year, or more often if reasonably necessary, during normal business hours and with at least ten (10) days prior notice, visit EPRO’s facility to observe the manufacture and
packaging of the Product, and/or to audit the facility for quality and to collect samples of the Product. 
 (b) A certificate of analysis
for each Batch delivered shall set forth the items tested, Specifications, and test results and a re-test date. EPRO shall send, or cause to be sent, such certificates to SPECTRUM prior to the shipment of Product (unless Product is shipped under
quarantine). SPECTRUM shall test, or cause to be tested, for release for further manufacturing, each Batch of Product as meeting the Specifications within thirty (30) days after receipts by SPECTRUM. 
 (c ) SPECTRUM’s payments for Product shipments received by SPECTRUM shall not constitute approval or acceptance of such Product. If the Product is
defective or does not conform to samples, descriptions or the Specifications attached hereto as Exhibits A and/or B, SPECTRUM is hereby granted the option to reject all shipped lots of the Product, accept all Batches, or accept any
Batchess thereof and reject the rest. EPRO shall reimburse SPECTRUM in full for those Products rejected and returned, and EPRO shall assume all costs of transportation and handling both ways. If not rejected within thirty (30) days, the Product
shall be deemed accepted. 
 (d) EPRO shall from time to time furnish to SPECTRUM upon reasonable written request, without charge,
pre-shipment samples of the Product that SPECTRUM needs for quality control, testing and evaluation. 
 (e) In case, EPRO does not agree that
the rejected Products are defective or the defectiveness of the Products has not been caused by EPRO, the Parties will appoint an 

  

 - 4 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 
independent third party expert whose results shall be final and binding. The costs for such procedure and the handling of the defective Product shall be
borne by the Party whose determination was in error. 
 (f) Unless otherwise stated, EPRO is responsible for compliance with cGMP and any
applicable United States, Canadian and Mexican Laws and any applicable local laws and regulations (“Regulations”) as they apply generally to production of drug substances at the site of manufacturing. SPECTRUM shall be responsible for
compliance with all Regulations as they apply to all other aspects of the use and sale of Product, which responsibility shall include, without limitation, all contact with the FDA regarding the foregoing. 
 Article 6 Warranties and Representations 
 (a) The
Product manufactured, processed and packaged hereunder shall be manufactured, processed and packaged in conformity with cGMP’s and the Specifications set forth in Article 1, Exhibits A and B of this Agreement. EPRO covenants, represents
and warrants that the Product shall be produced in accordance with cGMP. EPRO covenants, represents and warrants that it has obtained (or will obtain prior to producing the Product), and will remain in compliance with during the term of this
Agreement, all permits, licenses and other authorizations which are required under federal, state and local laws, rules and regulations applicable to the production only of the Product. 
 (b) All materials, ingredients, supplies and packaging materials utilized in the manufacture of Product sold hereunder shall be merchantable, of good
quality and fit for the purpose intended. 
 (c) EPRO has, and shall maintain during the term of this Agreement, the capability to
manufacture, package and deliver to SPECTRUM, under the terms of this Agreement, at least *** of the Product per month, if ordered by SPECTRUM. The Parties may adjust the required quantity from time to time. 
 (d) The execution of this Agreement and performance hereunder does not, and will not, abrogate, breach, or conflict with any agreement, mortgage, pledge,
or contract to which EPRO is a Party. 
 Article 7 Indemnities 
 EPRO shall assume all responsibility for and shall defend, indemnify and hold SPECTRUM and its directors, members, officers, employees, agents, consultants, shareholders, affiliates, toll manufacturer, partners or
advisors or those of its subsidiaries and/or affiliates (“Representatives”) harmless from and against any and all liability, losses, expenses, damages, assessments and claims, causes of action, settlement costs, including reasonable
attorney’s fees, or other liabilities of any kind (collectively, “Damages”) arising out of, resulting from or attributable to 
 (a) defects relating to a defective Product (defectiveness caused by EPRO); or 
  

 - 5 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 (b) material breach by EPRO of any term or provision of this Agreement; or 
 (c) negligent act or omission by EPRO and its Representatives; provided, that this (a) shall not obligate EPRO to indemnify SPECTRUM for any portion
of Damages directly attributable to, and directly caused by, the negligence or omission of SPECTRUM and/or its Representatives. 
 SPECTRUM
shall assume all responsibility for and shall defend, indemnify and hold EPRO and its Representatives harmless from and against any and all Damages arising out of, resulting from or attributable to: 
 (a) the use, sale, offer to sell, transfer or import of Product after acceptance by SPECTRUM; or 
 (b) material breach by SPECTRUM of any term or provision of this Agreement; or 
 (c) negligent act or omission by SPECTRUM and/or its Representatives; provided, that this (a) shall not obligate SPECTRUM to indemnify EPRO for any
portion of Damages directly attributable to, and directly caused by, the negligence or omission of EPRO and/or its Representatives. 
 A
party (the “Indemnitee”) which intends to claim indemnification under this Article 7 shall promptly notify the other party (the “Indemnitor”) in writing of any action, claim or other matter in respect of which the Indemnitee or
any of its Affiliates, or any of their respective directors, officers, employees, subcontractors, or agents, intend to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not
relieve the Indemnitor of any of its obligations hereunder except to the extent the Indemnitor is prejudiced by such failure. The Indemnitee shall permit, and shall cause its Affiliates, and their respective directors, officers, employees,
subcontractors and agents to permit, the Indemnitor, at its discretion, to settle any such action, claim or other matter, and the Indemnitee agrees to the complete control of such defense or settlement by the Indemnitor. Notwithstanding the
foregoing, the Indemnitor shall not enter into any settlement that would adversely affect the Indemnitee’s rights hereunder, or impose any obligations on the Indemnitee in addition to those set forth herein, in order for it to exercise such
rights, without Indemnitee’s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or other matter shall be settled without the prior written consent of the Indemnitor, which shall not be unreasonably
withheld or delayed. The Indemnitee, its Affiliates, and their respective directors, officers, employees, subcontractors and agents shall fully cooperate with the Indemnitor and its legal representatives in the investigation and defense of any
action, claim or other matter covered by the indemnification obligations of this Article 7. The Indemnitee shall have the right, but not the obligation, to be represented in such defense by counsel of its own selection and at its own expense.

 The indemnification obligations set forth in this Article shall survive the expiration or termination of this Agreement. 
 Article 8 Insurance 
  

 - 6 - 

 (a) EPRO shall procure and maintain, during the term of this Agreement and for a period one (1) year
beyond the expiration date of Product, comprehensive general liability insurance in the amount of $*** per occurrence and annual aggregate combined single limit for bodily injury and property damage liability and products liability insurance in the
amount of $*** per occurrence and annual aggregate combined single limit for bodily injury and property damage liability. All of such insurance coverage shall be maintained with an insurance company or companies having an A.M. Best rating of A
– VII or better. EPRO promptly shall deliver, upon written request by SPECTRUM, a certificate of EPRO’S insurance evidencing such coverage. 
 (b) SPECTRUM shall procure and maintain, during the term of this Agreement and for a period one (1) year beyond the expiration date of Product, comprehensive general liability insurance in the amount of $*** per
occurrence and annual aggregate combined single limit for bodily injury and property damage liability and products liability insurance in the amount of $*** per occurrence and annual aggregate combined single limit for bodily injury and property
damage liability. All of such insurance coverage shall be maintained with an insurance company or companies having an A.M. Best rating of A – VII or better. EPRO shall be named as an additional insured on the SPECTRUM insurance and SPECTRUM
promptly shall deliver, upon written request by EPRO, a certificate of SPECTRUM insurance and endorsement of additional insured to EPRO evidencing such coverage. 
 Article 9 Intellectual Property Rights 
 Rights to the intellectual property in the Product and the underlying Technology
shall be as set forth in the License Agreement. 
 Article 10 Assignment 
 This Agreement shall be binding upon and inure to the benefit of the successors or permitted assigns of each of the Parties and may not be assigned or transferred by either Party without the prior written consent of
the other, which consent will not be unreasonably withheld or delayed, except that no consent shall be required in the case of a transfer to a wholly-owned subsidiary or transaction with a third party involving the merger, consolidation or sale of
substantially all of the assets of the Party seeking such assignment or transfer and such transaction relates to the business covered by this Agreement and the resulting entity assumes all the obligations under this Agreement. No assignment shall
relieve any Party of responsibility for the performance of its obligations hereunder. 
 Article 11 Confidentiality 
 The Parties shall be bound to the same confidentiality provisions as set forth in Article III of the License Agreement and set forth in the Mutual Confidentiality
Agreement dated November 1, 2005. 
 Article 12 Term and Termination 
  

 - 7 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 (a) Subject to Article 2(c) above, this Agreement is effective on the Effective Date and shall remain in
full force and effect for as long as SPECTRUM is required to pay EPRO a royalty payment under Article V(A)(2)(a), (b), (c) or (d) under the License Agreement. This Agreement may be renewed only upon written agreement of the Parties.

 (b) Either Party may terminate this Agreement in the event of a material breach by the other Party of this Agreement that is not cured
within *** from notice of such breach by the non-breaching Party. 
 (c) Termination, expiration, cancellation or abandonment of this
Agreement through any means or for any reason, except as set forth in Articles 12(a) or 12(b), shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement.
The provisions of Articles 6, 7, 8, 9, 11, 12, 13, 15 and 16 hereof shall survive expiration or termination of this Agreement. 
 Article 13 Notices

 All notices under this Agreement shall be in writing and shall be either mailed, return receipt requested, to the addresses set forth
above or transmitted by facsimile, with confirmation of transmission, to the facsimile number listed below: 
  

			
	For EPRO:	  	Merck Eprova AG
		  	Im Laternenacker 5
		  	8200 Schaffhausen
		  	Switzerland
		  	Attention: Martin Ulmann
		  	Fax: ++41 (0)52 630 7255
		
	For SPECTRUM:	  	Spectrum Pharmaceuticals, Inc.
		  	157 Technology Drive
		  	Irvine, CA 92618
		  	U.S.A.
		  	Attention: V.P., General Counsel
		  	Fax: 1 (949) 788-6706

 Article 14 Scope of Agreement 
 This Agreement shall constitute the entire agreement between the Parties pertaining to the subject matter thereof. Neither Party is authorized to make any representation, warranty, or promise on behalf of the other
Party. No change, termination or attempted waiver of any of the provisions hereof shall be binding upon a Party unless signed by a duly authorized officer of the Party. Neither Party shall represent that it has power to bind the other Party or to
assume or to create any obligation or responsibility, expressed or implied, on behalf of the other Party. 
 Article 15 Dispute Resolution 

 

 - 8 - 
  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 Any and all disputes under the Agreement shall be settled in accordance with the dispute resolution
procedure set forth in Article XIII of the License Agreement. 
 Article 16 Applicable Law 
 This Agreement shall be construed in accordance with Article XI of the License Agreement. 
 Article 17 Severability 
 If any portion of this Agreement shall be in violation of any applicable
law, rule or regulation, such portion shall be inoperative, but the remainder of the Agreement shall remain valid and continue to bind the Parties. 
 Article 18 Independent Contractors 
 The Parties are independent contractors and engage in the operation of their own
respective businesses, and neither SPECTRUM nor EPRO shall be considered an employee, agent or joint venture partner of the other for any purpose whatsoever. Neither SPECTRUM nor EPRO shall have any authority to enter into any contracts or assume
any obligations for the other or to make any warranties or representations on behalf of the other. 
 Article 19 Headings, Interpretation 

The headings used in this Agreement are for convenience only and are not part of this Agreement. 
  
 SIGNATURE PAGE FOLLOWS 
  

 - 9 - 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective duly
authorized representatives on the day and year first above written. 
  

			
	 Merck Eprova AG

		
	By:	 	/s/ Martin Ulmann
		 	 Martin Ulmann

		
	Title:	 	 General Manager

		
	Date:	 	 June 1, 2006

  

			
		
	By:	 	/s/ Thomas Suter
		 	 Thomas Suter

		
	Title:	 	 Chief Financial Officer

		
	Date:	 	 June 1, 2006

  

			
	 Spectrum Pharmaceuticals, Inc.

		
	By:	 	/s/ Rajesh C. Shrotriya, M.D.
		 	Rajesh C. Shrotriya, M.D.
		
	Title:	 	 Chairman, CEO and President

		
	Date:	 	 May 19, 2006

  

 - 10 - 

 EXHIBIT A 
 SPECIFICATIONS 
 CALCIUM LEVOFOLINATE (L-CALCIUM FOLINATE) 
 SPECIFICATIONS for Purchase by SPECTRUM. 
  

 *** 

  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 
 PACKAGING GUIDELINES 
 *** 

  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 
 EPRO Bank Account 
 *** 

  

 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.Amendment dated as of August 8, 2006

 Exhibit 4.1 
 SECOND AMENDMENT TO RIGHTS AGREEMENT 
 SECOND AMENDMENT TO RIGHTS AGREEMENT (this
“Amendment”), dated as of August 8, 2006, to the Rights Agreement, dated as of December 10, 2001 (as amended by that certain amendment dated as of April 28, 2006, the “Agreement”), between ARAMARK
Corporation, a Delaware corporation (the “Company”), and Mellon Investor Services LLC, as rights agent (the “Rights Agent”). Capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed
to such terms in the Agreement. 
 WHEREAS, Section 27 of the Agreement provides that prior to the Distribution Date, the Company
and the Rights Agent shall, if the Company so directs, supplement or amend any provision of the Agreement without the approval of any holders of Rights; 
 WHEREAS, the Company proposes to enter into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”), by and among the Company, RMK Acquisition
Corporation, a Delaware corporation (“Merger Sub”), and RMK Financing LLC, a Delaware limited liability company providing for the merger (the “Merger”) of Merger Sub with and into the Company, with the Company
continuing as the surviving corporation; 
 WHEREAS, the Board of Directors of the Company has determined that, prior to the execution
of the Merger Agreement, it is necessary and desirable to amend the Agreement to exempt the Merger Agreement, the execution thereof and the transactions contemplated thereby, including, without limitation, the Merger, from the application of the
Agreement, in each case as set forth in this Amendment; and 
 WHEREAS, the Company has delivered to the Rights Agent a certificate,
dated as of the date hereof, of an appropriate officer of the Company certifying that this Amendment is in compliance with the terms of Section 27 of the Agreement and instructing the Rights Agent to execute and deliver this Amendment.

 NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of
which the parties hereby acknowledge, the parties agree as follows: 
  

	1.1.	Amendments to the Agreement. 

  

	 	(a)	The definition of “Acquiring Person” in Section 1(a) of the Agreement is amended by inserting the following as a new paragraph at the end of such definition:

 “Notwithstanding anything in this Section 1(a) to the contrary, none of (1) RMK Acquisition Corporation, a
Delaware corporation (“Merger Sub”), (2) RMK Finance LLC, a Delaware limited liability company (“SibCo”), (3) GS Capital Partners V Fund, L.P., J.P. Morgan Partners, LLC, 

 Warburg Pincus LLC and Thomas H. Lee Partners L.P. (collectively, the “Sponsors”), or
(4) Joseph Neubauer, nor any of their respective Affiliates or Associates, either individually, collectively or in any combination, shall be deemed to be an “Acquiring Person” solely by virtue of or as a result of the approval,
execution, delivery, adoption or performance of the Agreement and Plan of Merger, dated as of August 8, 2006, among the Company, Merger Sub and SibCo (as it may be amended or supplemented from time to time, the “Merger Agreement”)
or the consummation of the Merger (as defined in the Merger Agreement) or any other transactions contemplated thereby, including, without limitation, entry into or performance of the Voting Agreement (as defined in the Merger Agreement), the Equity
Rollover Commitment (as defined in the Merger Agreement), the Interim Investors Agreement (as defined in the Merger Agreement), the Sponsor Letter Agreements (as defined in the Merger Agreement) and the Equity Financing Letters (as defined in the
Merger Agreement) (in each case, as such agreement may be amended or supplemented from time to time) (such actions described in this sentence, the “Permitted Events”). 
  

	 	(b)	The definition of “Stock Acquisition Date” in Section 1(q) of the Agreement is amended by inserting the following sentence at the end thereof:

 “Notwithstanding anything in this Agreement to the contrary, a Stock Acquisition Date shall not be deemed to have
occurred solely by virtue or as a result of any Permitted Event or the public announcement of any Permitted Event.” 
  

	 	(c)	Section 3(a) of the Agreement is amended by inserting the following sentence at the end thereof: 

 “Notwithstanding anything in this Agreement to the contrary, a Distribution Date shall not be deemed to have occurred as the result of any Permitted
Event or the public announcement of any Permitted Event.” 
  

	 	(d)	Section 3 of the Agreement is amended by inserting the following sentence at the end thereof as new Section 3(d): 

 “Nothing in this Agreement shall be construed to give any holder of Rights or any other Person any legal or equitable rights, remedies or claims
under this Agreement by virtue of any Permitted Event.” 
  

	 	(e)	Section 7(a) of the Agreement is amended by deleting clause (i) thereof in its entirety and inserting in lieu thereof the following: 

 “(i) the earlier of (a) the Close of Business on November 10, 2011 and (b) immediately prior to the Effective Time (as defined in the
Merger Agreement), but only if the Effective Time shall occur, of the Merger (such earlier date, the “Final Expiration Date”). 
  

 2 

	 	(f)	A new Section 36 is added to read in its entirety as follows: 

 “Section 36. Termination. Notwithstanding anything herein to the contrary, immediately prior to the Effective Time (as defined in the Merger Agreement), but only if the Effective Time shall occur, (a) this Agreement shall
be terminated and be without further force and effect, (b) none of the parties to this Agreement will have any rights, obligations or liabilities hereunder and (c) the holders of the Rights shall not be entitled to any benefits, rights or
other interests under this Agreement; provided, however, that notwithstanding the foregoing, Sections 18 and 20 hereof shall survive the termination of this Agreement.” 
  

	1.2.	Agreement. The term “Agreement” as used in the Agreement shall be deemed to refer to the Agreement as amended hereby, and all references to the Agreement
shall be deemed to include this Amendment. 

  

	1.3.	Governing Law. This Amendment shall be deemed to be entered into under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance
with the laws of such State applicable to contracts to be made and performed entirely within such State. 

  

	1.4.	Counterparts. This Amendment may be executed in two or more counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such
counterparts shall together constitute but one and the same instrument. 

  

	1.5.	Effectiveness. This Amendment shall be effective as of the date hereof, and except as expressly set forth herein, the Agreement shall remain in full force and effect and
otherwise shall be unaffected hereby. 

  

 3 

 IN WITNESS WHEREOF, a duly authorized representative of each party has executed this Amendment, as
of the date first written above. 
  

			
	ARAMARK CORPORATION
		
	By:	 	 /s/ CHRISTOPHER HOLLAND

	Name:	 	Christopher Holland
	Title:	 	SVP and Treasurer
	
	MELLON INVESTOR SERVICES LLC
		 	As Rights Agent
		
	By:	 	 /s/ SAJOO J. SAMUEL

	Name:	 	Sajoo J. Samuel
	Title:	 	Client Relationship Director

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]